Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739537) titled 'PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses' on July 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: Massachusetts General Hospital
Condition:
Diabete Type 2
Pharmacogenomic Drug Interaction
Intervention:
Drug: Orforglipron
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: October 1, 2026
Target Sample Size: 100
To know more, visit https://clinicaltrials.gov/study/NCT07739537
Published by HT Digital Content Service...